{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:53:10Z","timestamp":1770292390529,"version":"3.49.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemotherapy for non-small cell lung cancer (NSCLC) can prolong survival and improve quality of life, but the majority of advanced stage patients succumb to disease within 2 years, meaning that there is room for improvement. The standard chemotherapy for NSCLC involves one of a number of chemotherapy doublets that have been shown to improve survival when compared with single agents or best supportive care. These doublets are generally comparable in terms of efficacy, differing primarily in their toxicity profiles. However, encouraging new options may be approaching, including therapies targeted to specific patient subpopulations, and the use of combinations of current and new drugs to produce synergistic effects.<\/jats:p><jats:p>Targeted therapies include the anti\u2013epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, EGFR monoclonal antibody cetuximab, and vascular endothelial growth factor (VEGF) inhibitors such as sorafenib, a small molecule TKI, and bevacizumab, a recombinant monoclonal VEGF antibody. Most attempts to combine EGFR-targeted therapies with standard chemotherapy in NSCLC have produced poor results, possibly as a result of antagonism between EGFR TKIs and chemotherapy. Positive results with bevacizumab suggest that VEGF-rather than EGFR-targeted therapies may produce better results when combined with chemotherapy.<\/jats:p><jats:p>Other new drugs being tested include enzastaurin, an oral serine threonine kinase inhibitor; vinflunine, a vinca alkaloid; dihydrofolate reductase inhibitors; and thymidylate synthase inhibitors.<\/jats:p><jats:p>Combinations of therapies, especially those acting via different mechanisms, hold promise for improvements in survival, but careful testing is required to determine optimum combinations of available drugs and where new drugs fit into the armamentarium.<\/jats:p>","DOI":"10.1634\/theoncologist.13-s1-37","type":"journal-article","created":{"date-parts":[[2008,2,8]],"date-time":"2008-02-08T18:53:04Z","timestamp":1202496784000},"page":"37-46","source":"Crossref","is-referenced-by-count":32,"title":["Conclusion"],"prefix":"10.1093","volume":"13","author":[{"suffix":"Jr.","given":"Paul A.","family":"Bunn","sequence":"first","affiliation":[{"name":"a University of Colorado Cancer Center, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Thatcher","sequence":"additional","affiliation":[{"name":"b Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,1,1]]},"reference":[{"key":"2021122208575991000_R1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/jnci\/djk195","article-title":"Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study","volume":"99","author":"Taguchi","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"18 suppl","key":"2021122208575991000_R2","first-page":"23S","article-title":"Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why?","volume":"20","author":"Bunn","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122208575991000_R3","first-page":"27","article-title":"Gemcitabine-containing regimens vs others in first-line treatment of NSCLC","volume":"18","author":"Natale","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"2021122208575991000_R4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2004.10.014","article-title":"Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes","volume":"47","author":"Le Chevalier","year":"2005","journal-title":"Lung Cancer"},{"key":"2021122208575991000_R5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.lungcan.2007.03.014","article-title":"A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer","volume":"57","author":"Jiang","year":"2007","journal-title":"Lung Cancer"},{"issue":"suppl 5","key":"2021122208575991000_R6","doi-asserted-by":"crossref","first-page":"v64","DOI":"10.1093\/annonc\/mdj953","article-title":"First line chemotherapy in advanced or metastatic NSCLC","volume":"17","author":"Rinaldi","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122208575991000_R7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122208575991000_R8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0169-5002(03)00233-2","article-title":"Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial","volume":"41","author":"Zatloukal","year":"2003","journal-title":"Lung Cancer"},{"key":"2021122208575991000_R9","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdf332","article-title":"Phase III randomized trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial","volume":"13","author":"Rosell","year":"2002","journal-title":"Ann Oncol"},{"key":"2021122208575991000_R10","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122208575991000_R12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D","article-title":"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group","volume":"92","author":"Shepherd","year":"2001","journal-title":"Cancer"},{"key":"2021122208575991000_R13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1008336931378","article-title":"Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial","volume":"11","author":"Manegold","year":"2000","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"2021122208575991000_R14","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1097\/01.JTO.0000283088.78970.9b","article-title":"Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). WCLC 2007 Presidential Symposium","volume":"2","author":"Scagliotti","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2021122208575991000_R15","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.21480","article-title":"Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer","volume":"104","author":"Zinner","year":"2005","journal-title":"Cancer"},{"key":"2021122208575991000_R16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-5002(01)00452-4","article-title":"Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: A phase II trial","volume":"36","author":"Masotti","year":"2002","journal-title":"Lung Cancer"},{"key":"2021122208575991000_R17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1023\/A:1008342116536","article-title":"Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer","volume":"11","author":"Belani","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122208575991000_R18","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1200\/JCO.1995.13.8.1860","article-title":"Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis","volume":"13","author":"Langer","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.1997.15.1.297","article-title":"Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study","volume":"15","author":"Crino","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.690.11.2","article-title":"Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial","volume":"11","author":"Scagliotti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122208575991000_R21","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non\u2013small-cell lung cancer: A Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R22","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R23","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non\u2013small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14 suppl","key":"2021122208575991000_R24","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1200\/jco.2004.22.90140.7061","article-title":"Long survival of never smoking non-small cell lung cancer (NSCLC) patients treated with erlotinib HCl (OSI774) and chemotherapy: Sub-group analysis of TRIBUTE","volume":"22","author":"Miller","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial \u2013 INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial \u2013 INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3816\/CLC.2006.n.021","article-title":"Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non small-cell lung cancer","volume":"7","author":"Davies","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"2021122208575991000_R29","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","article-title":"Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"2021122208575991000_R30","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1097\/01.JTO.0000283259.15347.56","article-title":"Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected, previously untreated NSCLC population: D2-03","volume":"2","author":"Kabbinavar","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2021122208575991000_R31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000093092","article-title":"Targeting the epidermal growth factor receptor in colorectal cancer: Advances and controversies","volume":"70","author":"Italiano","year":"2006","journal-title":"Oncology"},{"issue":"suppl 14","key":"2021122208575991000_R32","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/jco.2004.22.90140.7012","article-title":"Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)","volume":"22","author":"Rosell","year":"2004","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R33","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1200\/jco.2007.25.18_suppl.7643","article-title":"Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced\/metastatic non-small cell lung cancer (NSCLC)","volume":"25","author":"Belani","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R34","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/jco.2007.25.18_suppl.7539","article-title":"Gemcitabine\/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)","volume":"25","author":"Butts","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R35","volume-title":"Data Available From ERBITUX\u00ae Phase III Study in First-Line Treatment of Advanced Lung Cancer","author":"ImClone Systems Incorporated","year":"2007"},{"key":"2021122208575991000_R36","article-title":"Erbitux Phase III Study - FLEX Increases Overall Survival in First-Line Treatment of Non-Small Cell Lung Cancer","volume-title":"Press Release","author":"Merck","year":"2007"},{"key":"2021122208575991000_R37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122208575991000_R38","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1200\/JCO.2005.01.2823","article-title":"Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study","volume":"23","author":"Hirsch","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R39","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1200\/jco.2007.25.18_suppl.7547","article-title":"A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study","volume":"25","author":"Adjei","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3816\/CLC.2007.n.023","article-title":"A randomized phase II study of sorafenib\/gemcitabine or sorafenib\/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: Treatment rationale and protocol dynamics","volume":"8","author":"Gridelli","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"2021122208575991000_R41","volume-title":"A randomized (phase II), double-blind, multicenter phase I\/II trial of pemetrexed, carboplatin plus or minus sorafenib in the first-line treatment of patients with stage IIIb or IV non-small cell lung cancer","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R42","volume-title":"A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 439006) in chemonaive patients with stage IIIB-IV non-small cell lung cancer","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"18 suppl","key":"2021122208575991000_R44","doi-asserted-by":"crossref","first-page":"LBA7514","DOI":"10.1200\/jco.2007.25.18_suppl.lba7514","article-title":"Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-na\u00efve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704","volume":"25","author":"Manegold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R45","doi-asserted-by":"crossref","first-page":"18098","DOI":"10.1200\/jco.2007.25.18_suppl.18098","article-title":"Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)","volume":"25","author":"William","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R46","doi-asserted-by":"crossref","first-page":"18163","DOI":"10.1200\/jco.2007.25.18_suppl.18163","article-title":"Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer","volume":"25","author":"Dalsania","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R47","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1200\/jco.2007.25.18_suppl.7601","article-title":"Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results","volume":"25","author":"Patel","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ctrv.2006.07.003","article-title":"Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials","volume":"32","author":"Bria","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"2021122208575991000_R49","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1378\/chest.129.4.1031","article-title":"A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy","volume":"129","author":"Chen","year":"2006","journal-title":"Chest"},{"key":"2021122208575991000_R50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdj115","article-title":"Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial","volume":"17","author":"Camps","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122208575991000_R51","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/sj.bjc.6602241","article-title":"A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study","volume":"91","author":"Gridelli","year":"2004","journal-title":"Br J Cancer"},{"key":"2021122208575991000_R52","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"P\u00e9rez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208575991000_R54","volume-title":"Iressa web site","author":"AstraZeneca"},{"key":"2021122208575991000_R55","volume-title":"Gefitinib (Marketed as Iressa) Information. FDA Alert","author":"U.S. Food and Drug Administration\/Center for Drug Evaluation and Research","year":"2005"},{"key":"2021122208575991000_R56","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"2021122208575991000_R57","first-page":"1437","article-title":"[Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer.]","volume":"33","author":"Nishikawa","year":"2006","journal-title":"Gan To Kagaku Ryoho"},{"key":"2021122208575991000_R58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.lungcan.2005.02.011","article-title":"Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America","volume":"49","author":"Ho","year":"2005","journal-title":"Lung Cancer"},{"key":"2021122208575991000_R59","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","article-title":"Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer","volume":"24","author":"Hirsch","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R60","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R61","doi-asserted-by":"crossref","first-page":"7700","DOI":"10.1200\/jco.2007.25.18_suppl.7700","article-title":"Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC)","volume":"25","author":"Heist","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R62","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.1200\/jco.2006.24.18_suppl.7062","article-title":"A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer","volume":"24","author":"Fehrenbacher","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R63","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","article-title":"Phase I\/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R64","volume-title":"Atlas AVF 3671 (Genentech). A randomized, double-blind, placebo-controlled, phase IIIb trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R65","volume-title":"A phase, III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with Tarceva (erlotinib) compared with Tarceva alone for treatment of advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R66","first-page":"642","article-title":"A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory\/resistant patients with advanced non-small cell lung cancer: Final report","volume":"22","author":"Kim","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R67","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1200\/jco.2007.25.18_suppl.7698","article-title":"Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): A phase I-IIa dose-ranging study from the Hoosier Oncology Group","volume":"25","author":"Jalal","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R68","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1200\/JCO.2006.08.2263","article-title":"Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208575991000_R69","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1200\/jco.2006.24.18_suppl.2047","article-title":"Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer","volume":"24","author":"Hanauske","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R70","volume-title":"A randomized, open-label phase II study of pemetrexed (Alimta) plus carboplatin with or without enzastaurin hydrochloride, or docetaxel plus carboplatin as first line treatment in patients with advanced stage non-small cell lung cancer (NSCLC)","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R71","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6603106","article-title":"Vinflunine \u2013 an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: Results of a phase II study","volume":"94","author":"Bennouna","year":"2006","journal-title":"Br J Cancer"},{"issue":"18 suppl","key":"2021122208575991000_R72","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1200\/jco.2007.25.18_suppl.7511","article-title":"Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen","volume":"25","author":"Krzakowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122208575991000_R73","volume-title":"A two arm phase I dose escalation trial of vinflunine with erlotinib or pemetrexed in refractory solid tumors","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R74","volume-title":"A phase II single arm trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R75","volume-title":"LCCC 0503: Phase II study of vinflunine and cetuximab in the second line treatment of stage IIIB\/IV non-small cell lung cancer","author":"ClinicalTrials.gov"},{"key":"2021122208575991000_R76","first-page":"1611","article-title":"Pemetrexed disodium (Eli Lilly)","volume":"2","author":"Norman","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"2021122208575991000_R77","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1158\/0008-5472.CAN-05-2034","article-title":"BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors","volume":"65","author":"Gibbs","year":"2005","journal-title":"Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.13-S1-37","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.13-S1-37","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/S1\/37\/41832997\/oncolo_13_s1_37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/S1\/37\/41832997\/oncolo_13_s1_37.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T12:14:13Z","timestamp":1684239253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/S1\/37\/6397355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":77,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2008,1,1]]},"published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.13-s1-37","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,1,1]]},"published":{"date-parts":[[2008,1,1]]}}}